MARATTO

article · Frontiers in Cardiovascular Medicine

Opioid overdose and cardiovascular disease-related mortality: a retrospective analysis using real-world data from the USA, 1999–2023

2026Open accessTanta University

Abstract

Background: Cardiovascular disease (CVD) is a leading cause of mortality in the U.S., a burden amplified by the ongoing opioid epidemic. This study characterized long-term trends and disparities in mortality involving both opioid overdose and CVD from 1999 to 2023. Methods: We conducted a retrospective analysis using death certificate data from the CDC WONDER multiple cause-of-death files. Data for adults aged 15 and older were analyzed using ICD-10 codes for CVD (I00-I99) and opioid overdose (T40.0, T40.1, T40.2, T40.3, T40.4). Age-adjusted mortality rates (AAMRs) per 100,000 population and crude mortality rates (CMRs) were calculated. Joinpoint regression determined the average annual percent change (AAPC). Results: < 0.001). Men had consistently higher mortality than women (overall AAMRs: 2.51 vs. 0.99). Non-Hispanic (NH) Black individuals showed the steepest escalation in AAMR (from 0.33 in 1999 to 6.48 in 2023; AAPC: 12.45%). The West exhibited the highest overall AAMR (2.11). Non-metropolitan areas consistently showed higher AAMRs than metropolitan areas (overall AAMR: 1.56 vs. 1.47). Middle-aged adults aged 45-64 years had the highest overall CMR (2.94). Conclusion: Opioid overdose and CVD-related mortality surged, disproportionately impacting men, NH Black individuals, Western regions, and non-metropolitan areas.

Research topics

  • Opioid Use Disorder Treatment
  • Pain Management and Opioid Use
  • HIV, Drug Use, Sexual Risk

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3389/fcvm.2026.1771062

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.